Company profile
Dark Blue Therapeutics
Pioneering the next generation of precision oncology medicines to deliver a portfolio of transformative cancer therapies.
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
TM01 | Transaction MzUzMDc3MzgzNmFkaXF6a2N4
Published 06 Jul 2026 19:30
Last confirmation statement made up date
AA01 | Transaction MzUxNTM4NzExMmFkaXF6a2N4
Published 10 Apr 2026 13:43
Last accounts made up date
Company registered at Companies House
Dark Blue Therapeutics develops medical therapies, specialising in cancer treatments.
Dark Blue Therapeutics, an oncology focused spin-out from the LAB282 therapeutic accelerator program, is a pre-clinical biotech company tackling cancer with new therapies that target cancer cells' vulnerabilities and dependencies.
Dark Blue Therapeutics has secured additional external investment and is in the process of creating a novel drug pipeline
